Excess Intake of Macronutrients Clinical Trial
Official title:
Water and Coffee Intervention in Humans
Verified date | November 2023 |
Source | Region Skane |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
39 healthy subjects without medication (except oral contraceptives) aged 20-70 years are recruited via advertisements or through telephone contacts with individuals that had previously participated in population-based cohort studies in Malmö. All subjects are exposed to three different intervention procedures; water and coffee loads (acutely and chronically), or no change from usual fluid intake (as a time-control), respectively in randomized order. The daily intake of coffee or water will amount to 3 L of water and 1 L of coffee, respectively for one week each. The three interventions (water, coffee and control), are separated by three weeks of normal fluid intake as a wash-out period. By testing if simple life style interventions, i.e., increased water or coffee intake, may affect vasopressin secretion, evaluated as copeptin, we will increase the knowledge as to whether such life style induced changes of copeptin may in turn lead to effects on glucose tolerance as well as on other cardiometabolic risk factors previously shown to be associated with high copeptin level. Thus, the study will lead to further understanding about vasopressin and copeptin release and how life style manipulation of the vasopressin system may influence glucose metabolism and other cardiometabolic risk factors in healthy individuals.
Status | Completed |
Enrollment | 39 |
Est. completion date | December 31, 2016 |
Est. primary completion date | January 31, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 70 Years |
Eligibility | Inclusion Criteria: Healthy subjects Age 20-70 years Exclusion Criteria: medication (except oral contraceptives) any type of acute illness any type of chronic illness |
Country | Name | City | State |
---|---|---|---|
Sweden | Clinical research unit, Internal medicine department, Skåne University Hospital in Malmö | Malmö |
Lead Sponsor | Collaborator |
---|---|
Region Skane |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1 week result on plasma copeptin | Change ("?-value") between plasma copeptin value (pmol/L) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions. |
7 days | |
Secondary | 1 week result on plasma glucose | Change ("?-value") between plasma glucose (mmol/L) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions. |
7 days | |
Secondary | 1 week result on plasma insulin | Change ("?-value") between plasma insulin (IE) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions. |
7 days | |
Secondary | 1 week result on plasma glucagon | Change ("?-value") between plasma glucagon (pmol/L) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions. |
7 days | |
Secondary | 1 week result on plasma C-reactive protein | Change ("?-value") between plasma C-reactive protein (mg/L) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions. |
7 days | |
Secondary | 1 week result on plasma creatinine | Change ("?-value") between plasma creatinine (umol/L) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions. |
7 days | |
Secondary | 1 week result on plasma osmolality | Change ("?-value") between plasma osmolality (mosm/kg H2O) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions. |
7 days | |
Secondary | 1 week result on urine osmolality | Change ("?-value") between urine osmolality (mosm/kg H2O) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions. |
7 days | |
Secondary | 1 week result on blood pressure | Change ("?-value") between blood pressure (mmHg) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions. |
7 days | |
Secondary | Acute 4-hour effect of intervention on copeptin | To test the hypothesis that acute coffee or water load affects plasma copeptin levels (pmol/L), we will perform paired t-tests (or Wilcoxon's paired rank test in case of no normal distribution) between individual 0 min values (immediately before acute load) and repeated post load values taken each 30 min during 4 hours. | 4 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01587911 -
Casinomacropeptide and Satiety
|
N/A |